Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Will Glenmark-Celon’s ‘Substitutable’ Seretide Deliver In Europe?

Glenmark-Celon’s generic Seretide Accuhaler dry powder inhaler (DPI) has hit the Danish market but whether it can build momentum around its regulatory clearance for substitution remains to be seen.

Respiratory Generic Drugs

Piramal Critical Care Docks For China Push

Peter DeYoung, CEO of Piramal Critical Care, tells Scrip about his plans to take the group’s inhalation anesthesia portfolio to China and talks of the greater “competitive intensity” in the US amid quicker ANDA approvals by the FDA. Timelines around the potential US launch of the inhaled anesthetic agent, desflurane, however, appear hazy.
Commercial Strategy

Lupin Slumps To Q4 Loss Amid US Opioid Action But Build Up In Inhalation, Biosimilars

Lupin ended the fourth quarter in the red hit by an impairment provision related to the "underperforming" assets of its Gavis acquisition but the firm's US inhalation pipeline appears to have made some progress, including a filing for tiotropium dry powder inhaler (DPI). Early stage biosimilars under development include, among others, versions of Neulasta and Xgeva/Prolia.

Commercial Strategy

No Trial Waiver Sail-Through For Lilly’s Taltz In India?

Eli Lilly's Taltz (ixekizumab) may be staring at stretched launch timelines in India where competitor secukinumab already has a head start, after the US company's request for a local trial waiver for the product was turned down twice.

Research & Development Clinical Trials

Why Pharma Doesn't Always Keep Phase IV Promises In India

Are drug firms being lax when it comes to Phase IV studies in markets like India or are certain arbitrarily determined regulatory requirements largely to blame? Scrip delves into the issue.

Clinical Trials India

Can ‘Long-Term Partner’ Cipla Breathe New Life Into MannKind’s Afrezza?

Cipla is to commercialize the financially troubled MannKind’s inhaled insulin Afrezza in India, but it remains to be seen whether the deal can materially change the fortunes of the product.

Commercial Strategy
See All
Advertisement
UsernamePublicRestriction

Register